167 filings
10-Q
2024 Q1
CRNX
Crinetics Pharmaceuticals Inc
Quarterly report
9 May 24
4:38pm
8-K
CRNX
Crinetics Pharmaceuticals Inc
9 May 24
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results
4:12pm
8-K
CRNX
Crinetics Pharmaceuticals Inc
8 May 24
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
5:00pm
ARS
2023 FY
CRNX
Crinetics Pharmaceuticals Inc
25 Apr 24
Annual report to shareholders
4:50pm
DEFA14A
CRNX
Crinetics Pharmaceuticals Inc
25 Apr 24
Additional proxy soliciting materials
4:48pm
8-K
pwfld302pv5 gp
4 Apr 24
Departure of Directors or Certain Officers
4:52pm
S-3ASR
uv1993clv4e 69g5nn
19 Mar 24
Automatic shelf registration
4:05pm
8-K
35uzos3nu4ug0ypxo
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
6tnqlwleb 87uw5633ot
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
D
5onk3upajr6e
11 Mar 24
$350.00 mm in equity, sold $350.00 mm, 36 investors
4:15pm
S-8 POS
am0mjuyvzqi
1 Mar 24
Registration of securities for employees (post-effective amendment)
4:41pm
8-K
x578w1wsnb9g0ps7kmza
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
S-8
qm1cgxfkgl8 06f
28 Feb 24
Registration of securities for employees
6:04pm
8-K
snidvpdgqhi9kib
28 Feb 24
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
6r8i22km eoud
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
0lgkkwxzfpqs1
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
88hyom3
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:35pm
S-8
1q9pbxkl4fo5orux6ac
7 Nov 23
Registration of securities for employees
4:31pm